肿瘤细胞治疗研究
英文原题:Allogeneic Hematopoietic Stem Cell Transplantation for Mature T/NK-Cell Lymphomas in Children.
Allogeneic Hematopoietic Stem Cell Transplantation for Mature T/NK-Cell Lymphomas in Children.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
成熟T/NK细胞淋巴瘤(MTCLs)是一组异质性淋巴增殖性疾病,在成人和儿童中相对罕见。在某些情况下,异基因造血干细胞移植(HSCT)可作为巩固治疗考虑,并且是难治性形式和复发的首选。我们回顾性分析了19例在T细胞去除平台上接受单倍体或无关供者异基因造血干细胞移植的MTCL儿科患者。在所研究的患者中,5例诊断为皮肤T细胞淋巴瘤,4例为肝脾T细胞淋巴瘤,9例为ALK阳性间变性大细胞淋巴瘤,1例为鼻T/NK细胞淋巴瘤。所有患者均接受了基于treosulfan或全身照射的清髓性预处理。非复发死亡率为5%,5年复发或进展的累积发生率为27%,5年无事件生存率为67%,5年总生存率为78%。因此,我们的数据支持异基因T细胞去除HSCT可为高危成熟T细胞淋巴瘤儿童提供长期总生存期。
Mature T/NK-cell lymphomas (MTCLs) are a heterogeneous group of lymphoproliferative disorders, relatively rare in adults and children. Allogeneic hematopoietic stem cell transplantation (HSCT) can be considered in some cases as a consolidation and is the first choice for refractory forms and relapses.
We retrospectively analyzed 19 pediatric patients with MTCL who received allogeneic hematopoietic stem cell transplantation from a haploidentical or unrelated donor on the T cell depletion platform. Among the studied patients, cutaneous T-cell lymphoma was diagnosed in 5, hepatosplenic T-cell lymphoma in 4, ALK-positive anaplastic large cell lymphoma in 9 patients, and 1 had nasal T/NK cell lymphoma.
All patients received myeloablative conditioning based on treosulfan or total body irradiation. Non-relapse mortality was 5%, the cumulative incidence of relapse or progression at 5 years was 27%, 5-year event-free survival was 67%, and 5-year overall survival was 78%.
Thus, our data support that allogeneic T-cell-depleted HSCT can provide long-term overall survival of children with high-risk mature T-cell lymphomas.
MEMBER ACCOUNT
登录成功会直接打开下一页。